C-Path and PKDOC are excited to announce that four reports summarizing Sessions 1, 2, and 3B from the 2021 PKD Regulatory Summit have been published in The Clinical Journal of the American Society of Nephrology (CJASN). Please find the associated links below:
Drug Development for Cystic Kidney Diseases
Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease
Perspectives on Drug Development in Early ADPKD
Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD
The Summit brought together key stakeholders from the pharmaceutical industry and academic setting, foundations, patient advocacy groups, individuals living with PKD, and regulatory agencies from around the world to address current unmet drug development needs for PKD. Discussions were initiated to help identify and prioritize ongoing unmet needs in the PKD community and inform the launch of PKDOC 2.0 with stakeholder alignment and defined strategic focus.
